US Patent

US10898575 — Long-acting polymeric delivery systems

Method of Use · Assigned to Heron Therapeutics LLC · Expires 2035-04-20 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects long-acting polymeric delivery systems for active agents, including a local anesthetic of the "caine" classification.

USPTO Abstract

Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3118 — Bupivacaine Hydrochloride And Epinephrine
U-3118 — Bupivacaine Hydrochloride And Epinephrine
U-3118 — Bupivacaine Hydrochloride And Epinephrine
U-3118 — Bupivacaine Hydrochloride And Epinephrine

Patent Metadata

Patent number
US10898575
Jurisdiction
US
Classification
Method of Use
Expires
2035-04-20
Drug substance claim
No
Drug product claim
Yes
Assignee
Heron Therapeutics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.